{
  "metadata": {
    "export_date": "2026-01-05T18:28:37.213861",
    "patient_profile": {
      "age": 52,
      "sex": "female",
      "cancer_type": "NSCLC",
      "biomarkers": [
        "EGFR exon 19 deletion"
      ],
      "description": "52-year-old Asian female with EGFR-mutant (exon 19 deletion) metastatic NSCLC. Initially treated with osimertinib with excellent response lasting 18 months. Now progressed with new bone metastases and enlarging lung primary. Liquid biopsy shows acquired C797S resistance mutation. No CNS involvement. Interested in combination trials or next-generation EGFR inhibitors. Never smoker, excellent functional status. No significant comorbidities. Labs: all WNL including LFTs."
    },
    "total_trials": 60,
    "high_likelihood": 14,
    "medium_likelihood": 3
  },
  "results": [
    {
      "nct_id": "NCT03851445",
      "title": "LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)",
      "sponsor": "SWOG Cancer Research Network",
      "phase": "Phase 2/Phase 3",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Age: 52",
        "Sex: female",
        "Cancer type: NSCLC, confirmed by biomarker (EGFR exon 19 deletion)",
        "ECOG status: 0",
        "Prior therapies: osimertinib",
        "No brain metastases",
        "Country: United States"
      ],
      "conflicts": [],
      "uncertainties": [
        "No information on adequate tumor tissue available",
        "No confirmation on ctDNA testing",
        "Exact treatment line for osimertinib treatment prior to progression needs further validation"
      ],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type matches the trial's focus on NSCLC, and she has received prior systemic treatment (osimertinib) which is in line with the eligibility for previously treated patients. The patient meets other criteria like age and ECOG status, though there is some uncertainty regarding tumor tissue adequacy and ctDNA requirements.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05394831",
      "title": "A Phase 1/2, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of JIN-A02 in Patients With EGFR Mutant Advanced Non-small Cell Lung Cancer",
      "sponsor": "J Ints Bio",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Age: 52",
        "ECOG status: 0",
        "Cancer type: NSCLC",
        "Biomarker: EGFR exon 19 deletion",
        "Prior therapies: osimertinib (previously treated)",
        "No brain metastases",
        "Co-mutation: EGFR C797S"
      ],
      "conflicts": [],
      "uncertainties": [
        "Laboratory values (all WNL including LFTs not explicitly confirmed)",
        "Specific measurable lesion details not provided"
      ],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type (NSCLC) matches the trial's condition of studying advanced EGFR mutant NSCLC. The patient has previously been treated with osimertinib, which aligns with the trial's requirement for patients who have shown disease progression after standard treatment. The presence of the C797S mutation also fits well with the inclusion criteria for the study. No major conflicts were found, supporting a high likelihood of eligibility.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05498428",
      "title": "A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer",
      "sponsor": "Janssen Research & Development, LLC",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has histologically confirmed metastatic non-small cell lung cancer (NSCLC).",
        "Patient has EGFR exon 19 deletion mutation, which is required for the trial.",
        "Patient has ECOG status of 0, which is acceptable.",
        "Patient has no brain metastases, which meets the criterion."
      ],
      "conflicts": [],
      "uncertainties": [
        "All organ function labs are stated as WNL but specific values are not provided."
      ],
      "confidence": 0.85,
      "reasoning": "The patient has the appropriate cancer type (NSCLC) and confirmed biomarker (EGFR exon 19 deletion). The ECOG status is acceptable for enrollment. The only uncertainty relates to specific organ function lab values, but overall the patient condition and treatment line is compatible with the trial criteria.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05519293",
      "title": "A Phase I/IIa, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Anti-tumor Activity of H002 in Patients With Active EGFR Mutation Locally Advanced or Metastatic NSCLC",
      "sponsor": "RedCloud Bio",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has a confirmed diagnosis of metastatic NSCLC.",
        "Patient has an EGFR exon 19 deletion, which is an active EGFR mutation associated with TKI sensitivity.",
        "Patient has documented disease progression on osimertinib, a third-generation EGFR-TKI.",
        "ECOG status is 0, which is acceptable for trial participation.",
        "Patient has no brain metastases."
      ],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.85,
      "reasoning": "The patient has a diagnosis of metastatic non-small cell lung cancer (NSCLC) and an active EGFR mutation (exon 19 deletion). She has previously been treated with osimertinib and has documented disease progression, making her eligible for the previously treated patient category of this trial. All other relevant criteria are met.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06667076",
      "title": "A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
      "sponsor": "Janssen Research & Development, LLC",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Histologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC)",
        "Epidermal growth factor resistance-mutation (EGFRm) with exon 19 deletion",
        "ECOG performance status of 0",
        "No brain metastases"
      ],
      "conflicts": [],
      "uncertainties": [
        "Need verification of measurable lesions according to RECIST version (v)1.1",
        "Recovery status from prior therapy toxicities is not explicitly stated"
      ],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type matches the trial as they have advanced NSCLC with the required EGFR mutation. The patient is previously treated but the trial allows previously treated patients in the second-line setting. The ECOG status is acceptable, and there are no brain metastases. Minor uncertainties exist regarding measurable lesions and recovery from prior therapy, but overall fit is strong.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06907615",
      "title": "An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)",
      "sponsor": "Shanghai Henlius Biotech",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has metastatic NSCLC, which matches the trial's cancer type.",
        "Patient has previously received osimertinib, fulfilling the requirement of prior standard treatment failure.",
        "ECOG status is 0, meeting the trial's requirement.",
        "No brain metastases, which aligns with the eligibility criteria.",
        "The patient is aged 52, which meets the age requirement of being \u2265 18."
      ],
      "conflicts": [],
      "uncertainties": [
        "Need for confirmation of adequate organ function, though labs are stated to be within normal limits.",
        "Confirmation of prior treatment specifics beyond osimertinib (e.g., any platinum-based chemotherapy) is not explicitly provided."
      ],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type is metastatic NSCLC, which matches the target indication of the trial. The patient has received prior treatment (osimertinib) and is interested in further options. Although there are some uncertainties regarding organ function and specific prior treatments, the major eligibility criteria are satisfactorily met.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06659458",
      "title": "Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients",
      "sponsor": "Our Lady of the Lake Hospital",
      "phase": null,
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient is 52 years old.",
        "Patient is biologically born female.",
        "Patient is diagnosed with EGFR positive lung cancer (NSCLC, EGFR exon 19 deletion).",
        "Patient has an ECOG status of 0."
      ],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type (NSCLC with EGFR exon 19 deletion) matches the trial conditions, and the patient meets age and biological sex criteria. There are no conflicts or uncertainties regarding the provided eligibility criteria.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT04665206",
      "title": "Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients With Locally Advanced or Metastatic Solid Tumors",
      "sponsor": "Vivace Therapeutics, Inc",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has pathologically diagnosed metastatic NSCLC.",
        "Patient has exon 19 deletion, which is required for part of the trial."
      ],
      "conflicts": [],
      "uncertainties": [
        "Organ function labs are reported as WNL but not explicitly detailed."
      ],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type is NSCLC, which is an eligible condition for the trial. The patient has an exon 19 deletion, making her suitable for the combination cohort. She is also ECOG 0, meeting the performance status requirement. The only uncertainty is the explicit confirmation of organ functions, but overall, she meets the other critical eligibility criteria.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT04314401",
      "title": "Cancer Moonshot Biobank Research Protocol",
      "sponsor": "National Cancer Institute (NCI)",
      "phase": null,
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Cancer type is NSCLC, which matches the trial conditions studied",
        "Patient is currently progressing on a regimen of standard of care therapy",
        "Age is 52, which meets the minimum age requirement of 13",
        "ECOG status is 0, which is acceptable"
      ],
      "conflicts": [],
      "uncertainties": [
        "No information provided on whether archival tissue is available",
        "No information on assessments of organ function labs"
      ],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type is non-small cell lung cancer (NSCLC), which is eligible for the trial. The patient is previously treated with osimertinib and is currently progressing, fitting the treatment line requirements. All other core eligibility criteria are met, with only minor uncertainties regarding archival tissue and organ functions.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05736029",
      "title": "PROPHETIC Extended - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Extended Study.",
      "sponsor": "OncoHost Ltd.",
      "phase": null,
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Age: 52",
        "Sex: female",
        "Cancer type: NSCLC",
        "ECOG status: 0"
      ],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type (NSCLC) directly matches the trial's conditions. The patient is previously treated with osimertinib, which fits within the scope of the trial focusing on previously treated patients. The patient's age and ECOG score are within accepted limits, ensuring no conflicts with inclusion criteria.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06131840",
      "title": "An Open-label Phase 1 Study to Investigate PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors",
      "sponsor": "Seagen, a wholly owned subsidiary of Pfizer",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Cancer type is NSCLC, which is included in the trial conditions studied.",
        "ECOG status is 0, which meets the eligibility criteria."
      ],
      "conflicts": [],
      "uncertainties": [
        "Patient's organ function labs are reported as WNL but specifics are not provided."
      ],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type of NSCLC matches the trial's conditions, and the ECOG status is acceptable. The only uncertainty is regarding specific organ function details, which do not necessarily disqualify the patient.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT07090499",
      "title": "A Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants With Advanced Solid Tumors.",
      "sponsor": "Pfizer",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Age is 52, which meets the age requirement of 18 years or older.",
        "ECOG status is 0, which is within the acceptable range of 0-1.",
        "The patient has advanced non-small cell lung cancer (NSCLC), which matches the trial's conditions studied.",
        "The patient has measurable disease as indicated by new bone metastases and enlarging lung primary.",
        "Patient has experienced progression following standard treatment with osimertinib."
      ],
      "conflicts": [],
      "uncertainties": [
        "Exact resolution status of acute effects of prior anticancer therapy is not explicitly stated.",
        "Details regarding the requirement for pre-treatment tumor tissue submission are unclear."
      ],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type matches the trial's indication for advanced NSCLC, and she has progressed after prior treatment, fitting into the previously treated category. The ECOG status and age are acceptable; however, there are some minor uncertainties about acute effects and tumor tissue submission.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06706076",
      "title": "A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)",
      "sponsor": "BlossomHill Therapeutics",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has NSCLC, which matches the trial focus.",
        "Patient has an EGFR mutation (exon 19 deletion), qualifying for the trial's mutation criteria.",
        "Patient has an ECOG status of 0.",
        "Patient has received prior standard therapy (osimertinib), which fits the previous treatment requirement."
      ],
      "conflicts": [],
      "uncertainties": [
        "No specific information about the presence of measurable target extracranial lesions.",
        "No explicit mention of organ function lab values (all WNL)."
      ],
      "confidence": 0.75,
      "reasoning": "The patient's cancer type (NSCLC) and biomarker (EGFR exon 19 deletion) match the trial requirements, and the patient has prior treatment, which is acceptable for this phase of the study. The primary uncertainties involve the presence of measurable lesions and organ function lab values, but since other criteria are met, the patient likely qualifies.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06562192",
      "title": "Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers",
      "sponsor": "Novartis Pharmaceuticals",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Age (52) is greater than 18 years old",
        "Cancer type (NSCLC) matches the trial conditions studied",
        "ECOG status (0) indicates excellent functional status",
        "No brain metastases present",
        "Prior therapies (osimertinib) align with treatment line criteria"
      ],
      "conflicts": [],
      "uncertainties": [
        "Lesions showing 68Ga-NNS309 uptake (not provided in patient profile)",
        "Lab values for absolute neutrophil count, hemoglobin, platelet count, and creatinine clearance (not provided)"
      ],
      "confidence": 0.75,
      "reasoning": "The patient's cancer type (NSCLC) matches the trial criteria. The patient is 52 years old and has no brain metastases, while their ECOG status is 0. They have previously been treated with osimertinib, which aligns with the trial's inclusion criteria for patients who have actionable genomic alterations and have progressed following targeted therapy. However, there is uncertainty regarding the lesion uptake of 68Ga-NNS309 and missing organ function lab values.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06660407",
      "title": "Grid Radiotherapy for Advanced Non-Small Cell Lung Cancer at the Time of Progression on Immune Checkpoint Inhibition",
      "sponsor": "Mayo Clinic",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "MEDIUM",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Age is 52 years (\u2265 18 years)",
        "ECOG status is 0",
        "Cancer type is NSCLC and is Stage IV",
        "No brain metastases, which is allowed",
        "No ongoing systemic treatment or steroids"
      ],
      "conflicts": [
        "Currently progressing on osimertinib indicates the patient is not on standard of care first-line immunotherapy or chemoimmunotherapy, which may conflict with eligibility"
      ],
      "uncertainties": [
        "No details on recent lab values including hemoglobin, ANC, platelet count, and liver function tests",
        "No clear indication if the patient has an extracranial lesion \u2265 3 cm amenable to grid therapy"
      ],
      "confidence": 0.65,
      "reasoning": "The patient's cancer type and stage match the trial's requirements. However, it is unclear if she qualifies based on progressing on osimertinib as her current treatment, as the trial looks for patients progressing on standard first-line immunotherapy or chemoimmunotherapy. Additionally, there are uncertainties regarding her most recent lab results and the size of metastases if any exist.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06975293",
      "title": "Open-label, Non-randomized, Multi-cohort, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of STC-15 (a METTL3 Inhibitor) as a Part of Combination Therapy With Toripalimab in Participants With Selected Advanced Cancers",
      "sponsor": "STORM Therapeutics LTD",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "MEDIUM",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Age: 52",
        "ECOG status: 0",
        "Cancer type: NSCLC",
        "Biomarkers: EGFR exon 19 deletion",
        "No brain metastases"
      ],
      "conflicts": [
        "Prior therapies: osimertinib. The trial requires progression on prior anti-PD-1/L1 therapy, which the patient has not received."
      ],
      "uncertainties": [
        "Patient's eligibility based on having received anti-PD-1 therapy.",
        "Documented radiologic assessment of progression on the prior therapy before study entry is unspecified.",
        "Measurable disease according to RECIST v1.1 is unspecified."
      ],
      "confidence": 0.65,
      "reasoning": "The patient's cancer type (NSCLC) matches the trial's indication. However, they have not received an anti-PD-1/L1 therapy, which is a requirement for eligibility, leading to uncertainties regarding eligibility based on treatment line criteria.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05501665",
      "title": "SiCARIO (Split Course Adaptive Radioimmunotherapy) for the Treatment of Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Using Biologically-Adaptive Radiotherapy - A Phase I/II Study",
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "MEDIUM",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Age: 52",
        "ECOG status: 0",
        "Cancer type: NSCLC is consistent with trial conditions studied",
        "Biomarker: PD-L1 TPS is 5% which meets the requirement for assessment but does not qualify for any threshold",
        "No brain metastases"
      ],
      "conflicts": [
        "Prior therapies: patient has previously received osimertinib which may conflict with the treatment line requirement depending on the interpretation of trial descriptions"
      ],
      "uncertainties": [
        "Assessment of required organ function (labs all WNL not explicitly stated)",
        "Patient\u2019s eligibility for immunotherapy-based systemic regimens is not explicitly stated",
        "Geographic bio-markers for eligibility are not provided; patient is located in the United States"
      ],
      "confidence": 0.5,
      "reasoning": "The patient has a diagnosis of NSCLC, which matches the trial conditions, but has previously been treated, and it's unclear whether treatment line criteria align with the trial's requirements. This introduces significant uncertainty, affecting confidence in eligibility.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06262321",
      "title": "Phase II Trial of Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax",
      "sponsor": "University of Rochester",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has targetable EGFR mutation (exon 19 deletion), while the trial requires non-targetable NSCLC."
      ],
      "uncertainties": [],
      "confidence": 0.95,
      "reasoning": "The patient's cancer type (NSCLC with EGFR mutation) does not match the trial criteria which exclude patients with targetable mutations.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT04165070",
      "title": "KEYMAKER-U01 Substudy 01A: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab With or Without Chemotherapy in Treatment-Naive Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)",
      "sponsor": "Merck Sharp & Dohme LLC",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has received prior systemic treatment (osimertinib) for metastatic NSCLC while the trial specifically includes only treatment-naive participants."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient's cancer type (NSCLC) matches the trial's focus; however, the patient's prior treatment history with osimertinib excludes her from eligibility as the trial seeks treatment-naive participants.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT04181060",
      "title": "Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)",
      "sponsor": "National Cancer Institute (NCI)",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has advanced NSCLC (ECOG 0, no brain metastases, and classified as metastatic).",
        "Patient has a pathologically-confirmed diagnosis of non-squamous NSCLC.",
        "Patient has a somatic activating sensitizing mutation in EGFR (exon 19 deletion).",
        "Patient has an ECOG status of 0."
      ],
      "conflicts": [
        "Patient has received prior treatment with osimertinib, which is an EGFR TKI, but this trial excludes prior anti-VEGF treatment, meaning the patient is not eligible to be treated under this study as specified in the eligibility criteria."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient has metastatic non-small cell lung cancer with an EGFR mutation, which matches the trial's disease criteria. However, the patient has received osimertinib as a prior treatment, and this disqualifies her from eligibility under the treatment line criteria since the trial requires no prior treatment with EGFR TKIs.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05671510",
      "title": "Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors",
      "sponsor": "OncoC4, Inc.",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Age: 52",
        "Sex: female",
        "Cancer type: NSCLC",
        "Biomarkers: EGFR exon 19 deletion",
        "ECOG status: 0",
        "Brain metastases: none"
      ],
      "conflicts": [
        "Patient has documented actionable mutations in EGFR, which is excluded by the trial criteria."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient's cancer type (NSCLC) matches the trial, but the presence of an actionable mutation (EGFR) leads to exclusion as per the trial's exclusion criteria.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06452277",
      "title": "A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations",
      "sponsor": "Bayer",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has non-small cell lung cancer (NSCLC) with EGFR mutation, while trial is for patients with HER2-activating mutations.",
        "Patient has prior systemic therapy (osimertinib), while trial excludes participants with prior systemic therapy for metastatic disease."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient has NSCLC with an EGFR mutation, which does not align with the trial's focus on HER2 mutations. Additionally, the patient has previously been treated with osimertinib, which also conflicts with the trial's eligibility criteria for treatment-naive patients.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06644768",
      "title": "A Multicenter, Randomized, Open-Label, Phase 1b/2 Trial Of Valemetostat Tosylate Plus Pembrolizumab Vs Pembrolizumab Alone in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 With Tumor Proportion Score \u226550% Without Actionable Genomic Alterations",
      "sponsor": "Daiichi Sankyo",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Age: 52",
        "Sex: female",
        "Cancer type: NSCLC",
        "Biomarkers: EGFR exon 19 deletion",
        "ECOG status: 0",
        "Brain metastases: none"
      ],
      "conflicts": [
        "Key inclusion criterion states: 'Has no prior systemic therapy for advanced or metastatic disease.' - Patient has received osimertinib."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient's NSCLC matches the trial focus; however, the trial requires treatment-naive patients and the patient has previously received osimertinib, leading to exclusion.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT00897117",
      "title": "Molecular Fingerprinting of Lung Cancer",
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "phase": null,
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Diagnosis of non-small cell lung cancer"
      ],
      "conflicts": [
        "Patient has received prior systemic therapy (osimertinib) but trial excludes patients treated with chemotherapy before surgery."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient's cancer type matches the trial, but the trial specifically excludes patients who have received systemic therapy prior to surgery. The patient has prior therapy (osimertinib), thus they are excluded from eligibility.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05415358",
      "title": "A Prospective Study Of Immune Signatures In Metastatic Non-Small Cell Lung Cancer (mNSCLC) Patients At Completion Of Immune Checkpoint Inhibitor Treatment Either As Monotherapy Or In Combination With Chemotherapy In The First Line Setting",
      "sponsor": "Wake Forest University Health Sciences",
      "phase": null,
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has received prior therapy (osimertinib) but trial requires patients who have completed first line immune checkpoint inhibitor treatment."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient's cancer type matches the trial focus on metastatic NSCLC; however, the patient does not meet the treatment line criteria as they have previously received osimertinib, whereas the trial requires patients who have completed first-line immune checkpoint inhibitor treatment. Therefore, the patient is excluded.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05443126",
      "title": "A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0031 in Patients With Advanced RET-altered Malignancies",
      "sponsor": "Ellipses Pharma",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has EGFR mutations (exon 19 deletion and C797S) which are major driver alterations other than RET as required by the trial."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient's cancer type does not match the trial requirements as it specifies RET-altered malignancies, whereas the patient has NSCLC with EGFR mutations, making them ineligible.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05985655",
      "title": "A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors",
      "sponsor": "Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "ECOG status is 0",
        "Age is 52",
        "No brain metastases",
        "Patient has advanced NSCLC"
      ],
      "conflicts": [
        "Patient has progressed after prior osimertinib treatment which indicates they are not treatment-naive, while the trial criteria specify advanced solid tumors that are previously treated."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient's cancer type matches the trial conditions (NSCLC). However, the patient is not treatment-naive, as they have previously received osimertinib. Trial eligibility criteria indicate that this trial includes previously treated patients. Therefore, the patient's prior treatment excludes them from eligibility.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT07223424",
      "title": "Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (PSI-Immune)",
      "sponsor": "Diwakar Davar",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient is previously treated with osimertinib, trial requires treatment-naive patients."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient's cancer type (NSCLC) does match the trial conditions being studied, but the patient is not treatment-naive as they have already been treated with osimertinib. This directly conflicts with the trial's inclusion criteria for previously treated patients, leading to exclusion.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT07223047",
      "title": "A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 As Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies",
      "sponsor": "Bristol-Myers Squibb",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient's cancer type is NSCLC; trial requires participants with a KRAS alteration but patient has EGFR mutation."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient's diagnosis of non-small cell lung cancer (NSCLC) does not meet the trial's requirement for a KRAS alteration, leading to a clear exclusion.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06150664",
      "title": "A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-8371 in Patients With Advanced Malignancies",
      "sponsor": "Compass Therapeutics",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient is 52 years old and meets the age criterion (18 years or older).",
        "ECOG status is 0, meeting the performance status requirement."
      ],
      "conflicts": [
        "Patient has not received 2 doses of PD-1/PD-L1 therapy, which is required for NSCLC eligibility.",
        "Patient has not received prior platinum-based chemotherapy, which is required for NSCLC eligibility."
      ],
      "uncertainties": [
        "No specific information on laboratory results is provided.",
        "No geographic restrictions mentioned for the trial."
      ],
      "confidence": 0.1,
      "reasoning": "The patient's cancer (NSCLC) indicates a mismatch with the trial requirements since she has not received 2 doses of PD-1/PD-L1 therapy or prior platinum-based chemotherapy. Therefore, the patient is likely excluded.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06945484",
      "title": "PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study",
      "sponsor": "University of Utah",
      "phase": "Not Applicable",
      "status": "Not yet recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient diagnosed with NSCLC (non-small cell lung cancer)"
      ],
      "conflicts": [
        "Patient is previously treated with osimertinib, which conflicts with the trial's requirement for neoadjuvant chemotherapy or immunotherapy and surgery."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient's cancer type matches the trial; however, they are previously treated with osimertinib, which conflicts with the trial's exclusion criteria for patients who are not treatment-naive.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT03551951",
      "title": "Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers and Subjects Undergoing Lung Cancer Screening",
      "sponsor": "University of Missouri-Columbia",
      "phase": null,
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has previously been treated with osimertinib; the trial appears to require treatment-naive patients."
      ],
      "uncertainties": [],
      "confidence": 0.09,
      "reasoning": "The patient's cancer type matches NSCLC, but the trial likely excludes previously treated patients, which the patient is due to her treatment history with osimertinib.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05430009",
      "title": "Phase I Trial of Feasibility and Safety of Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer",
      "sponsor": "VA Ann Arbor Healthcare System",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "ECOG status: 0"
      ],
      "conflicts": [
        "Patient has no liver metastases, while trial specifically studies patients with liver metastases."
      ],
      "uncertainties": [],
      "confidence": 0.09,
      "reasoning": "The patient's cancer type matches the trial indication; however, the patient does not have liver metastases, which is a critical requirement for participation in this trial.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06119581",
      "title": "SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression \u226550% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression",
      "sponsor": "Eli Lilly and Company",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has EGFR mutation (exon 19 deletion), while trial requires KRAS G12C mutation.",
        "Patient has prior treatment with osimertinib, while trial requires treatment-naive patients."
      ],
      "uncertainties": [],
      "confidence": 0.05,
      "reasoning": "The patient's cancer type is NSCLC with an EGFR mutation, while the trial specifically targets KRAS G12C mutations. Furthermore, the patient has previously been treated with osimertinib, which is not compatible with the trial's requirement for treatment-naive patients.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT04155034",
      "title": "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)",
      "sponsor": "SWOG Cancer Research Network",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has NSCLC, but trial is for small-cell lung cancer (SCLC)."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "Patient's cancer type is non-small cell lung cancer (NSCLC), which does not match the trial's focus on small-cell lung cancer (SCLC). Therefore, the patient is clearly excluded.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05061550",
      "title": "A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)",
      "sponsor": "AstraZeneca",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has a sensitising EGFR mutation (exon 19 deletion) which excludes eligibility for this trial focused on resectable NSCLC without such mutations."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient's cancer type does not match the trial indication since the trial excludes participants with sensitising EGFR mutations, and the patient has an exon 19 deletion.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05715229",
      "title": "A Multicenter Phase II Randomized Trial Of Immunotherapy Versus Chemotherapy Guided By Circulating Tumor DNA-Based Molecular Response On Patients With Metastatic NSCLC",
      "sponsor": "Hackensack Meridian Health",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has a prior treatment with osimertinib while the trial specifies that eligible patients will have newly diagnosed, previously untreated, histologically documented Stage IV NSCLC."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient's cancer type matches the trial's focus on NSCLC, but the patient has received prior therapy with osimertinib, which excludes them from eligibility as the trial requires treatment-naive patients.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05800587",
      "title": "Phase II Study of Dose Attenuated Chemotherapy in Patients With Lung Cancer and Age > 70 and/or Comorbidities",
      "sponsor": "Fox Chase Cancer Center",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has received prior therapy (osimertinib), but trial does not state eligibility for previously treated patients."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient's cancer type (NSCLC) is within the scope of the trial, but given that the trial does not specify eligibility for previously treated patients, and the patient has a history of treatment, she is excluded.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05853575",
      "title": "A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation",
      "sponsor": "Mirati Therapeutics Inc.",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has advanced NSCLC",
        "Patient is 52 years old",
        "Patient has ECOG status of 0"
      ],
      "conflicts": [
        "Trial targets patients with KRAS G12C mutation, patient has EGFR C797S mutation instead and does not have KRAS G12C",
        "Trial requires prior treatment with chemotherapy including cisplatin or carboplatin, patient has not received this type of treatment",
        "Trial requires prior treatment with an immune checkpoint inhibitor, patient has not received this type of treatment"
      ],
      "uncertainties": [
        "No uncertainty in the provided information, all criteria clearly defined"
      ],
      "confidence": 0.0,
      "reasoning": "The patient's cancer type does not match the trial's target indication, as the trial is for patients with KRAS G12C mutation while the patient has an EGFR mutation. Additionally, the patient's prior therapies do not align with trial eligibility criteria.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06162572",
      "title": "A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression",
      "sponsor": "Servier Bio-Innovation LLC",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "ECOG status 0"
      ],
      "conflicts": [
        "Patient has prior systemic treatment (osimertinib) but trial requires treatment-naive patients.",
        "Patient has an EGFR mutation, which is an exclusion criterion as the trial does not accept participants with driver mutations."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient's cancer type (NSCLC) matches the trial; however, due to prior treatment with osimertinib and the presence of an EGFR mutation, the patient is ineligible according to the trial's criteria.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06246110",
      "title": "A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer",
      "sponsor": "Eikon Therapeutics",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has received prior systemic therapy (osimertinib) for metastatic NSCLC, while trial requires no prior systemic treatment for advanced/metastatic NSCLC."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient's cancer type is NSCLC, which is applicable to the trial. However, the patient received prior systemic therapy (osimertinib), and the trial specifically excludes patients who have received prior systemic treatment for advanced/metastatic NSCLC. Therefore, the patient is ineligible.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06788912",
      "title": "KEYMAKER-U01 Substudy 01E: A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)",
      "sponsor": "Merck Sharp & Dohme LLC",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has previously received osimertinib, while the trial requires treatment-naive patients."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient's cancer type is NSCLC, which matches the trial. However, the trial requires treatment-naive patients, and the patient has a history of prior therapy with osimertinib, leading to a clear exclusion.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06712316",
      "title": "A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer",
      "sponsor": "BioNTech SE",
      "phase": "Phase 2/Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "ECOG status of 0"
      ],
      "conflicts": [
        "Patient has NSCLC with an actionable epidermal growth factor receptor (EGFR) mutation (exon 19 deletion), while the trial does not allow patients with actionable EGFR mutations."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient's cancer type of NSCLC with an actionable EGFR mutation does not match the trial\u2019s requirement, which excludes patients with such mutations. Thus, the patient is excluded from eligibility.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT07216404",
      "title": "Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY)",
      "sponsor": "Alan Davis",
      "phase": "Phase 2",
      "status": "Not yet recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has a confirmed diagnosis of NSCLC."
      ],
      "conflicts": [
        "Patient has prior therapy (osimertinib), while the trial requires treatment-naive patients."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient has a diagnosis of NSCLC, which matches the trial's focus. However, the trial likely excludes patients who have received prior treatments, and the patient has previously been treated with osimertinib, leading to a clear exclusion.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT07063745",
      "title": "A Randomized Phase 2/3 Study of BMS-986504 in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion",
      "sponsor": "Bristol-Myers Squibb",
      "phase": "Phase 2/Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "ECOG status: 0",
        "Cancer type: NSCLC"
      ],
      "conflicts": [
        "Patient has prior systemic therapy (osimertinib) for metastatic NSCLC, while the trial requires no prior systemic therapy for metastatic disease."
      ],
      "uncertainties": [
        "Ability to meet other protocol-defined inclusion/exclusion criteria"
      ],
      "confidence": 0.0,
      "reasoning": "The patient has NSCLC, but the trial requires no prior systemic therapy for metastatic disease, which the patient does not meet due to prior treatment with osimertinib.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT07220096",
      "title": "Registry Trial and Needs Assessment of Patients With Young-onset Lung Cancer: Impact of a Dedicated Care Program on Patient Experience and Outcomes",
      "sponsor": "M.D. Anderson Cancer Center",
      "phase": null,
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Patient age 52 is above maximum age 50"
    },
    {
      "nct_id": "NCT04712877",
      "title": "LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancers",
      "sponsor": "Lung Cancer Mutation Consortium",
      "phase": null,
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has metastatic NSCLC (stage not eligible) while trial includes stage IA2-III NSCLC.",
        "Patient is previously treated with osimertinib while trial does not accept previously treated patients."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient has metastatic lung cancer, which does not match the early-stage focus of the trial, and they are previously treated, which conflicts with the treatment-naive requirement.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05866302",
      "title": "Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients. A Multi-center, Observational Trial.",
      "sponsor": "University of Michigan Rogel Cancer Center",
      "phase": null,
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has NSCLC which does not match the trial's focus on Chronic Lung Disease and Hematopoietic Cell Transplantation."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient's cancer type (NSCLC) does not match the conditions studied in the trial, which is focused on chronic lung disease and GVHD following hematopoietic cell transplantation.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06343402",
      "title": "A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study",
      "sponsor": "TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "The trial is for patients with a KRAS G12C mutation, while the patient has an EGFR exon 19 deletion. This is a clear exclusion based on disease type."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient's cancer type (NSCLC with EGFR mutation) does not match the trial's focus on KRAS G12C mutations, resulting in a clear exclusion.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT02143830",
      "title": "A Phase II Trial of HSCT for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine",
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05058651",
      "title": "Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients With Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)",
      "sponsor": "National Cancer Institute (NCI)",
      "phase": "Phase 2/Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05684965",
      "title": "A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX301 in Patients With Advanced Solid Tumors",
      "sponsor": "Xilio Development, Inc.",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05785741",
      "title": "A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1310 in Subjects With Advanced/Metastatic Solid Tumors",
      "sponsor": "DualityBio Inc.",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06730750",
      "title": "A Phase 1/2a, Multicenter, Open-label, First in Human Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors",
      "sponsor": "Bristol-Myers Squibb",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT07023731",
      "title": "A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors",
      "sponsor": "Arvinas Inc.",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT03420963",
      "title": "Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults",
      "sponsor": "M.D. Anderson Cancer Center",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Patient age 52 is above maximum age 40"
    },
    {
      "nct_id": "NCT04423029",
      "title": "A Phase 1/1b, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications",
      "sponsor": "Dragonfly Therapeutics",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06475807",
      "title": "Cancer Nutrition Study: CaNS - A Pilot Study of Dietary Interventions in Cancer Patients Treated With Immune Checkpoint Inhibitors",
      "sponsor": "University of Pittsburgh",
      "phase": "Not Applicable",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06555744",
      "title": "A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors",
      "sponsor": "Zymeworks BC Inc.",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05799274",
      "title": "Characterizing the Radiochemical and Radiation Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Ductal Adenocarcinoma or Other Solid Tumors",
      "sponsor": "Radiopharm Theranostics, Ltd",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Age: 52",
        "Sex: female",
        "Cancer type: NSCLC",
        "ECOG status: 0",
        "PD-L1: TPS 5%",
        "Prior therapies: osimertinib",
        "Brain metastases: none",
        "Country: United States"
      ],
      "conflicts": [
        "The trial is for patients with a history of PDAC, NSCLC, or other solid tumors but specifically mentions new or residual disease indicated by SOC imaging; patient has new bone metastases and an enlarging lung primary, which is not confirmed as new or residual per SOC within the required timeframe."
      ],
      "uncertainties": [
        "Specific lab values to confirm inclusion criteria and eligibility based on organ function are not provided.",
        "No details on prior clinical trials and whether patient meets exclusion criteria for previous study participation."
      ],
      "confidence": 0.0,
      "reasoning": "The patient's cancer type matches with NSCLC, but the requirement of confirming new or residual disease through SOC imaging within 12 weeks has not been established in the patient's profile, leading to exclusion.",
      "excluded_reason": null
    }
  ]
}